Familial benign hypercalcemia (FBH) and neonatal hyperparathyroidism (NHPT) are disorders of calcium homeostasis that are associated with missense mutations of the calcium-sensing receptor (CaR). We have undertaken studies to characterize such CaR mutations in FBH and NHPT and to explore methods for their more rapid detection. Nine unrelated kindreds (39 affected, 32 unaffected members) with FBH and three unrelated children with sporadic NHPT were investigated for mutations in the 3,234-bp coding region of the CaR gene by DNA sequencing. Six novel heterozygous (one nonsense and five missense) mutations were identified in six of the nine FBH kindreds, and two de novo heterozygous missense mutations and one homozygous frame-shift mutation were identified in the three children with NHPT. Our results expand the phenotypes associated with CaR mutations to include sporadic NHPT. Single-stranded conformational polymorphism analysis was found to be a sensitive and specific mutational screening method that detected > 85% of these CaR gene mutations. The single-stranded conformational polymorphism identification of CaR mutations may help in the distinction of FBH from mild primary hyperparathyroidism which can be clinically difficult. Thus, the results of our study will help to supplement the clinical evaluation of some hypercalcemic patients and to elucidate further the structure-function relationships of the CaR.
Introduction
The human calcium-sensing receptor (CaR)' is a 1,078-amino acid cell surface protein which is expressed in the parathyroids, 1 . Abbreviations used in this paper: CaR, calcium-sensing receptor; FBH, familial benign hypercalcemia; MENI, multiple endocrine neoplasia type 1; NHPT, neonatal hyperparathyroidism; SSCP, single-stranded conformational polymorphism; SSO, sequence-specific oligonucleotide.
thyroid C cells, and kidney, and is a member of the family of G protein-coupled receptors (1, 2) . The CaR gene is located on chromosome 3q21-q24 and loss of function mutations have been reported in the hypercalcemic disorders of familial benign hypercalcemia (FBH) and neonatal hyperparathyroidism (NHPT) (3) (4) (5) and a gain of function mutation has been reported in the hypocalcemic disorder referred to as autosomal dominant hypocalcemia (6) . FBH, which is also referred to as familial hypocalciuric hypercalcemia, is an autosomal dominant disorder with a high degree of penetrance, that is characterized by lifelong asymptomatic hypercalcemia in association with an inappropriately low urinary calcium excretion (7) (8) (9) (10) (11) . A normal circulating parathyroid hormone (PTH) concentration and mild hypermagnesemia are also typically present (9, 11) . Although most patients with FBH are asymptomatic, chondrocalcinosis and acute pancreatitis have occasionally been observed to occur (7, 8, 11) . In addition, children of consanguineous marriages within FBH kindreds have been observed to have life-threatening hypercalcemia due to severe NHPT (10) (11) (12) (13) (14) . These children suffer from failure to thrive, dehydration, bony undermineralization, rib cage deformities, multiple fractures, and hypotonia in the first weeks of life and these complications often necessitate urgent parathyroidectomy ( 10, (12) (13) (14) . These two hypercalcemic disorders may represent the differential effects of gene dosage, as FBH has been reported to be associated with heterozygous mutations in the CaR gene in nine kindreds whereas NHPT was associated with a homozygous mutation in two of these kindreds (3, 4) . However, the relationship between NHPT and FBH is often unclear as some patients with NHPT lack a family history of FBH and appear to be sporadic, whereas others may have a milder phenotype with a self-limiting course (11, (14) (15) (16) (17) (18) . In addition, the clinical importance of FBH lies in its differentiation from primary hyperparathyroidism, and it has been reported that 10% of patients in whom hypercalcemia failed to respond to parathyroid surgery had FBH (7-11, 14, 19) . The diagnosis of FBH relies on the interpretation of urinary calcium excretion values taken together with a family history of hypercalcemia or failed parathyroid surgery (7) (8) (9) . However, there may not be a clear distinction between FBH and primary hyperparathyroidism on the basis of urinary calcium excretion alone (7-9, 11, 14) , and in small kindreds a family history may be difficult to elicit. To supplement the clinical evaluation of such patients, we have undertaken studies to characterize the spectrum of CaR mutations with the aim of facilitating a molecular genetic screening strategy.
Methods
Family 16/94 Family 18 (9, 20, 21) , and the clinical details of the probands from these and other families are summarized in Table I . In addition, persistent hypercalcemia after parathyroid surgery has been observed in individuals 11-2 from family 16/94, I-1 and 11-1 from family 04/89, II-1 from family 11/94, 11-4 and I-4 from family 18/94, 11-2 and 111-6 from family 23/92, 11-3 and 111-5 from family 11/91, and 11-4, 11-5, and H1-6 from family 02/94 (Fig. 1) . Histological examination of the parathyroids revealed either normal parathyroid tissue or chief cell hyperplasia in all cases. Three patients who suffered from NHPT (Table I ) but in whose families there was no evidence of hypercalcemia were investigated together with their family members (Fig. 1 ). All three children with NHPT had presented with neonatal hypercalcemia which was associated with marked bony undermineralization. Parathyroidectomy and histological examination revealed chief cell hyperplasia of all four parathyroid glands in the three NHPT children who all became hypocalcemic and required vitamin D replacement postoperatively; the clinical courses of individual 11-1 from family 18/92 and individual 11-2 from family 08/93 have been reported previously (18, 22) . The parents and siblings ( Fig. 1 ) of the three children with NHPT were normocalcemic (Table I). DNA hybridization and microsatellite polymorphism analysis. DNA from leukocytes, fixed paraffin-embedded parathyroid, and animal tissues was prepared by standard methods (23, 24) , and DNA from semen was prepared by washing twice with PBS, lysing with 0.2 M potassium hydroxide and 50 mM DTT at 650C for 10 (Fig. 2) . Restriction fragment length polymorphisms and microsatellite polymorphisms were detected using previously described methods (23) (24) (25) (26) were designed to amplify exons 2 to 7, and 9 of the 12 intron/exon boundaries; the 7 novel primers are indicated in bold and the DNA sequences of the remaining 17 primers have been reported previously (3). Corp., Cleveland, OH) protocol was performed as described previously (27) . DNA sequence abnormalities in the probands, which were confirmed either by restriction endonuclease analysis or by hybridization to sequence-specific 32P-end labeled 19-mer oligonucleotides (SSO) as described previously (23, 27) , were demonstrated to cosegregate with the disorder and to be absent in the DNA obtained from 55 unrelated individuals. Primers 7FF and 6BR were also used to investigate the conservation of the sixth transmembrane domain of the CaR in the nine species: African green monkey, Aotus monkey, marmoset, pig, horse, cow, rabbit, hamster, and mouse, using the conditions described above, with the exception of the annealing temperature which was reduced to 60°C for rodent DNA. Single-stranded conformational polymorphism (SSCP) analysis. Genomic DNA from a proband and 10 unrelated normal individuals was used with appropriate primers (Fig. 2) for PCR amplification, as described above, and the PCR products were analyzed for SSCP using the Phast electrophoresis system (Pharmacia LKB, Uppsala, Sweden) as follows. A 3-yl aliquot of the PCR product was diluted with 6 ml of 66% formamide, denatured at 95°C for 5 min, cooled on ice for 3 min, and 2 ,ul was loaded onto a precast 12.5 or 20% polyacrylamide gel with natural buffer strips (Pharmacia LKB), which had been precooled to the required electrophoresis temperature. Gel electrophoresis was performed at either 10, 15, or 20°C and at 210-350 Vh depending upon the size of the fragment. The gel was fixed in: 10% ethanoic acid and 50% ethanol for 10 min; 5% glutaraldehyde for 5 min; 5% ethanoic acid and 10% ethanol for 10 min. Silver staining with 0.025 M aqueous silver nitrate for 10 min revealed the SSCPs which were scored by two independent observers (D. Trump and R. V. Thakker), who were blinded to the identity of the samples.
Results
Mutations in FBH families. Segregation analysis in the nine FBH families (Fig. 1) did not exclude an association between FBH and the haplotypes obtained with the six microsatellite polymorphic loci from chromosome 3q21-q24, and an analysis of the Southern blots obtained with the two intragenic DNA probes from exons 4 and 7 did not reveal any deletion or rearrangement of the CaR gene. DNA sequence analysis was therefore performed, and an investigation of the entire 3,234-bp coding sequence of the CaR gene from each of the nine probands revealed the presence of six novel heterozygous point mutations (Table III) . Thus, five of the six mutations were missense mutations and one was a nonsense mutation, and all occurred within the exons that encode either the extracellular or the transmembrane domains of the CaR (Fig. 2) , and none occurred in the 3' segment of exon 7 that encodes the intracellular tail of the receptor. The occurrence of each of these mutations in the six probands of families 11/91, 16 (Fig. 1) was confirmed either by SSO hybridization analysis (Fig. 3) or by restriction enzyme analysis (Fig. 4) to cosegregate with FBH. In addition, the absence of these DNA sequence abnormalities in 110 alleles from 55 unrelated normal individuals established that these abnormalities were mutations and not functionally neutral polymorphisms which would be expected to occur in > 1% of the population. (Table  II) : a proline at codon 55 to leucine within the amino-terminal exon 2 (P55L); a tyrosine to a serine at codon 218 in exon 4 (Y218S); a neutral glycine to a charged arginine at codon 670 within the second transmembrane domain in exon 7 (G670R); and a charged arginine to a cysteine at codon 680 within the first extracellular loop in exon 7 (R680C). The fifth missense mutation was a GTC-ATC transition at codon 817 in family 04/89 (Fig. 1) and this would result in the substitution of a valine residue by an isoleucine (Table III) within the sixth transmembrane domain in exon 7 (V8171). This substitution is conservative as valine and isoleucine are both hydrophobic, nonpolar aliphatic amino acids differing structurally only by one methylene group. The significance of this alteration was therefore further investigated by a comparative analysis of the predicted amino acid sequence of the sixth transmembrane domain in 10 mammalian species. This revealed a 100% conservation of all the 22 amino acids of the sixth transmembrane domain, including the Val 817 residue, and indicated that the V8171 substitution was likely to be of functional significance.
Mutations in NHPT patients. Examination of the 3,234-bp coding region of the CaR gene in the three unrelated children with NHPT ( Fig. 1) showed different de novo heterozygous missense mutations R227L and C582Y in the children from families 08/93 and 08/94 (Fig. 5) , respectively, and a combined homozygous C to T transition and a l-bp deletion involving codon 747 in the child from family 18/92 (Fig. 6 ). Nonpaternity was excluded for each of these children by the demonstration of shared alleles for each of the five highly polymorphic loci D3S1303, D3S1267, D11S533, D13S260, and Rbl.20 (25 (Fig. 6) , and the mutation which predicted a frameshift gave rise to a 28-amino acid stretch of missense peptide in which a stop signal (TGA) occurred at codon 776. This mutation at codon 747 was associated with the loss of an HhaI site and was used to confirm that the proband 11-1 was homozygous for the mutation and that his normocalcemic parents were heterozygous (Fig. 6 ). Both Fig. 7 . SSCP analysis of the smaller PCR fragments of < 300 bp, such as those encompassing exon 2 (primers IF to IR) and the 5' portion of exon 7 (primers 7GF to 6AR), readily detected the point mutations. However, SSCP analysis of the larger PCR fragments (> 350 bp) such as those from primers 6BF to 7ER required the conditions to be optimized before some of the mutations could be identified (Fig. 7) . The details of these conditions for SSCP analysis for each of the PCR products are shown along with the primer sequences in Table II . Using these conditions only one mutation (V8171) could not be detected by SSCP analysis, and this may be due to the large size of this PCR product which may give the single DNA strand greater stability in the gel in a single structural conformation (28) . Our SSCP analysis of > 200 individual PCR products of the CaR gene did not consistently detect any other abnormal bands, thereby indicating an absence of false-positive results. Thus, SSCP analysis proved to be a sensitive and reliable method in the detection of eight of these nine mutations.
Discussion
Our results have identified nine novel mutations of the CaR gene in six families with FBH and three children with NHPT and these mutations are of help in speculating upon the structurefunction relationships of the CaR. The human CaR which consists of 1,078 amino acids (Fig. 2) is predicted to have: a large 612 amino acid extracellular, presumably calcium-binding domain; seven transmembrane domains with three intracellular and three extracellular loops; and an intracellular tail ( 1-3, 29) . The amino acid sequence of the CaR is highly conserved and the human CaR shares 93% overall amino acid identity with both the bovine and rat CaRs (1-3, 29, 30 ). This conservation between the human and bovine sequences is more marked within the extracellular and the transmembrane domains each of which shares 96 and 98% amino acid identity, respectively (1, 2), than within the intracellular tail which shares only 82% amino acid identity. Thus, this comparative analysis suggests that the structure of the intracellular domain is less critical to gous for the C582Y mutation and was not associated with an allelic loss that would indicate a role for the CaR as a tumor suppressor gene. In addition, an analysis of DNA from the father's semen (I-IS) revealed an absence of the mutation, thereby indicating that he was unlikely to have germ line mosaicism. Analysis of 55 unrelated normocalcemic individuals (N. 3 shown) revealed an absence of the C582Y mutation, thereby confirming that it is not a common DNA sequence polymorphism. Thus, NHPT is associated with a heterozygous de novo mutation in this family. A similar analysis in family 08/93 demonstrated that a de novo heterozygous R227L mutation (Table III) was also associated with NHPT. function than that of the highly conserved extracellular and transmembrane domains, and the report of three functionally neutral amino acid polymorphisms within the intracellular tail (31) and our nine hypercalcemia-associated mutations which were either within the extracellular or transmembrane domains of the receptor support this prediction.
Our nine mutations of the CaR gene (Table IH) (Table  HI) and P747 frame-shift mutations (Fig. 6 ) predict the occurrence of truncated proteins of 606 and 775 amino acids, respectively and, if expressed, each would likely result in a nonfunctional CaR. The remaining seven CaR mutations are all missense substitutions and these, together with the 11 previously reported missense mutations (3, 5, 31 ) , all involve structurally significant amino acid changes at residues that are conserved between human, rat, and bovine CaRs (1, 2, 30) . For instance, the codon Y218S and R227L mutations (Table HI) occur within an area of the receptor proposed to be important for ligand-binding (1) and the C582Y mutation occurs at one of the 20 conserved cysteine residues that may maintain the secondary structure of the CaR (1, 30) . The V8171 mutation (Table III) The child (II-1) was confirmed to be homozygous for the mutation but both parents, who were normocalcemic, were heterozygous for the mutation. These DNA sequence abnormalities of codon 747 were not observed in 55 unrelated normocalcemic individuals. Thus, in family 18/92, the homozygous mutation at codon 747 is associated with NHPT and -the heterozygous mutation is associated with normocalcemia in both father (I-1) and mother (1) (2) (Table I) (Fig. 6) , the R680C mutation of family 02/94, and the G670R mutation of family 23/92 (Fig. 3) , respectively. These PCR products were derived using the primers 6BF and 7ER (Table II) , and all three mutations found by DNA sequencing of this PCR product were detectable by SSCP analysis using the conditions described in Table II. have therefore explored the use of the SSCP technique for the more rapid screening of CaR mutations. Our results demonstrated that SSCP was a useful, sensitive, and specific method that was successful in the detection of > 85% of the CaR mutations in our families. Although the sensitivity of SSCP is dependent upon the size of the DNA fragment (28) , we were able to identify three mutations within a 423-bp PCR product by using optimized conditions (Table II) . Thus, our findings indicate that mutational analysis using SSCP may be of help in supplementing the clinical evaluation of asymptomatic hypercalcemic patients who may have equivocal urinary calcium excretion studies or in whom a family history is difficult to elicit.
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context of an FBH family is associated with a homozygous affected haplotype or homozygous missense mutations. These genetic differences may be reflected in the clinical heterogeneity of NHPT in which some children may have a severe disorder with a high mortality ( 10, (12) (13) (14) and other children may have a milder disorder with a self-limiting course ( 1 1, 14-18 ). Thus, in the NHPT children of families 08/93 and 08/94 ( Fig. 1) who had heterozygous mutations, the elevations of serum calcium (Table I) were observed to be modest when compared with those observed in the NHPT child of family 18/92, who had a homozygous mutation, and whose serum calcium was similar to that observed in some other NHPT children ( 10-14, 17, 18) . This mild neonatal expression in the NHPT children with de novo heterozygous CaR mutations may also be comparable with the mild NHPT phenotype that has been observed in the heterozygous FBH children who have inherited a paternal mutation and are born to normocalcemic mothers (15, 16) . In this situation the prevailing maternal normocalcemia may cause varying degrees of fetal parathyroid hyperplasia, depending upon the severity of the underlying set-point abnormality (11, 14) , and this together with the skeletal response to PTH may determine the severity of the neonatal hypercalcemia.
FBH may be difficult to differentiate from mild primary hyperparathyroidism on the basis of PTH estimation and urinary calcium excretion alone, as illustrated by families 04/89 and 11/91 (Table I ). In addition, family histories and investigations from small kindreds (e.g., family 19/89, Fig. 1 ) may not reveal the presence of FBH, and the occurrence of familial primary hyperparathyroidism, either as an isolated endocrinopathy or as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome (39) may also make the distinction between FBH and these disorders difficult (7-9, 11, 14, 19) . The identification of CaR mutations in these instances may be of help, as illustrated by family 02/94 (Fig. 1) . However, the mutational diversity within the 3,234 bp of the CaR gene (3-5, 31) makes mutational screening for FBH by a direct DNA sequencing approach in patients with hypercalcemia time-consuming. We
